VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification

Age and Ageing
Martin WehlingH Frohnhofen

Abstract

to further validate the FORTA (Fit fOR The Aged) concept, a bicentric randomised, controlled trial was run in two geriatric clinics. patients (≥65 years, ≥3 drugs or ≥60 years, ≥6 drugs) with three relevant diseases and hospitalisation for ≥5 days were randomised. In the intervention, but not the control group, a FORTA team instructed ward physicians on FORTA. FORTA is the first positive/negative listing approach labelling medications used to treat chronic illnesses in older patients from A (indispensable), B (beneficial), C (questionable) to D (avoid). The primary end point was the FORTA score: sum of medication errors classified as over-, under- and mistreatment. Consecutive patients were randomised to the intervention and control ward; outcome assessment was blinded. four hundred and nine patients (age 81.5 years, 64% female, hospitalisation 17.4 days) were included. The primary end point was significantly (P < 0.0001) more reduced in the intervention versus control groups (2.7 ± 2.25 versus 1 ± 1.8, mean ± SD, intergroup comparison of admission/discharge differences). Over- and under-treatment scores and use of A (increase) and D (decrease) drugs were significantly improved (P < 0.01). The total number of adverse drug react...Continue Reading

References

Jan 16, 2002·JAMA : the Journal of the American Medical Association·David W KaufmanAllen A Mitchell
Dec 10, 2003·Mayo Clinic Proceedings·Rubin Bressler, Joseph J Bahl
Dec 18, 2003·British Journal of Clinical Pharmacology·A A Mangoni, S H D Jackson
Oct 13, 2004·Archives of Internal Medicine·Jerry H Gurwitz
Apr 13, 2005·Archives of Internal Medicine·Andrea CorsonelloUNKNOWN Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA) Investigators
Oct 19, 2006·JAMA : the Journal of the American Medical Association·Daniel S BudnitzJoseph L Annest
Jan 26, 2008·International Journal of Clinical Pharmacology and Therapeutics·P GallagherD O'Mahony
Jun 30, 2011·Deutsche medizinische Wochenschrift·H FrohnhofenM Wehling
Mar 2, 2012·Journal of the American Geriatrics Society·UNKNOWN American Geriatrics Society 2012 Beers Criteria Update Expert Panel
Sep 6, 2013·Journal of the American Board of Family Medicine : JABFM·Steven M OrnsteinCara B Litvin
Mar 19, 2014·Age and Ageing·Matteo TosatoUNKNOWN Investigators of the CRIME Study
Aug 17, 2014·European Journal of Clinical Pharmacology·Carina MichalekHelmut Frohnhofen

❮ Previous
Next ❯

Citations

Oct 21, 2016·Journal of the American Medical Directors Association·Martin Wehling
Mar 21, 2018·MMW Fortschritte der Medizin·Joachim Zeeh
Apr 18, 2018·Geriatrics & Gerontology International·Ivana IvanovaRobert Vander Stichele
Jan 16, 2018·F1000Research·Bronagh McDonnell, Lori Ann Birder
Jan 11, 2018·Therapeutic Advances in Drug Safety·Doron Garfinkel
Sep 4, 2018·The Cochrane Database of Systematic Reviews·Audrey RankinCarmel Hughes
Aug 24, 2019·Zeitschrift für Gerontologie und Geriatrie·Olaf KrauseUlrike Junius-Walker
Mar 28, 2019·Canadian Journal on Aging = La Revue Canadienne Du Vieillissement·Sharmin S BalaPrasad S Nishtala
Mar 13, 2020·Expert Opinion on Drug Metabolism & Toxicology·Farhad Pazan, Martin Wehling
Apr 20, 2018·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Gulistan BahatMehmet Akif Karan
May 5, 2018·Zeitschrift für Gerontologie und Geriatrie·Ulrich Thiem
Feb 12, 2019·Drugs & Aging·L J SeppalaUNKNOWN EuGMS Special Interest Group on Pharmacology
Sep 25, 2017·Zeitschrift für Gerontologie und Geriatrie·Martin Wehling
Feb 26, 2019·Therapeutic Advances in Drug Safety·Denis CurtinDenis O'Mahony
Jan 27, 2019·European Journal of Clinical Pharmacology·Farhad PazanMartin Wehling
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Armin ShahrokniMartine T E Puts
Jan 5, 2021·Deutsche medizinische Wochenschrift·Heinrich Burkhardt
Apr 7, 2017·Deutsches Ärzteblatt International·Martin Wehling
Aug 28, 2019·Deutsches Ärzteblatt International·Torsten Kratz, Albert Diefenbacher
Apr 7, 2017·Deutsches Ärzteblatt International·Hannah Haumann
Feb 15, 2021·European Geriatric Medicine·Jean-Baptiste BeuscartOlivia Dalleur
Feb 20, 2021·Das Gesundheitswesen·Susanne Helene Bauer, Stefan Gronemeyer
Mar 6, 2021·Neurological Research and Practice·Juraj Kukolja, Jens Kuhn
Mar 12, 2021·European Geriatric Medicine·Farhad Pazan, Martin Wehling

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.